Company: RGBP
Filing Date: 2025-09-08
Form Type: 253G1
Source: 0001641172-25-026822
Chunk: 109

Company: Regen BioPharma Inc
Filing Date: 2025-09-08
Form: 253G1
Chunk 109
---
 application further to Phase III clinical trials.

The Company is currently engaged in actively identifying
small molecules that inhibit or express NR2F6 leading to immune cell activation for oncology applications and immune cell suppression
for autoimmune disease.

The Company is in the early stages of development
of its proposed products and therapies. The Company will be required to obtain approval from the FDA in order to market any of The Company’s
products or therapies. No approval has been granted by the FDA for the marketing and sale of any of the Company’s products and therapies
and no assurance may be given that any of the Company’s products or therapies will be granted such approval. The Company’s
current plans include the development of regenerative medical applications up to the point of successful completion of Phase I and/ or
Phase II clinical trials after which the Company would either attempt to sell or license those developed applications or, alternatively,
advance the application further to Phase III clinical trials. The Company can provide no assurance that the Company will be able to sell
or license any product or that, if such product is sold or licensed, such sale or license will be on terms favorable to the Company.

A. BASIS OF ACCOUNTING

The financial statements have been prepared using
the basis of accounting generally accepted in the United States of America. Under this basis of accounting, revenues are recorded as earned
and expenses are recorded at the time liabilities are incurred. The Company has adopted a September 30 year-end.

B. PRINCIPLES OF CONSOLIDATION

The consolidated financial statements include the
accounts of KCL Therapeutics, Inc., a Nevada corporation and wholly owned subsidiary of Regen. Significant inter-company transactions
have been eliminated.

C. USE OF ESTIMATES

The preparation of consolidated financial statements in conformity with GAAP requires the Company to make estimates and assumptions that affect the amounts reported in our consolidated financial statements and the accompanying notes. Such estimates include accounts receivables, accrued liabilities, income taxes, long-lived assets, and deferred tax valuation allowances. These estimates generally involve complex issues and require management to make judgments, involve analysis of historical and future trends that can require extended periods of time to resolve, and are subject to change from period to period. In all cases, actual results could differ materially from estimates.

| 89 |

D. REVERSE STOCK SPLIT

On March 6, 2023, the Company
filed a Certificate of Amendment (the “Certificate of Amendment”) to the Company’s Certificate of Incorporation to effect
a reverse stock